Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: Emcure’s move to take Gennova to 100% ownership and fold it under the “One Emcure” framework tightens control over a strategically important biologi...
Key Highlights: Implications: Sun Pharma’s acquisition of Innovcare looks like a portfolio-building move in India: for about ₹271.2 crore, Sun is buying a growing busin...
